{"id":62298,"date":"2025-12-04T10:05:24","date_gmt":"2025-12-04T09:05:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/"},"modified":"2025-12-04T10:05:24","modified_gmt":"2025-12-04T09:05:24","slug":"labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/","title":{"rendered":"LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\/ML-driven Antibody Optimisation Programmes"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (<b>EVA\u2122<\/b>) to optimise potential therapeutic NANOBODY\u00ae proteins for multiple new targets<\/i>\n<\/li>\n<\/ul>\n<p>LONDON&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/AI?src=hash\" target=\"_blank\">#AI<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Flabgeniustx.com%2F&amp;esheet=54364500&amp;newsitemid=20251204759388&amp;lan=en-US&amp;anchor=LabGenius+Therapeutics&amp;index=1&amp;md5=820bd6da61224d7a6770cc4d0782832e\" rel=\"nofollow\" shape=\"rect\">LabGenius Therapeutics<\/a> (\u201cLabGenius\u201d), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with Sanofi. This collaboration combines LabGenius\u2019 AI\/ML-driven antibody design capabilities with Sanofi\u2019s expertise in the development of therapeutic <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sanofi.com%2Fen%2Fmagazine%2Four-science%2Fnanobody-technology-platform&amp;esheet=54364500&amp;newsitemid=20251204759388&amp;lan=en-US&amp;anchor=NANOBODY%26%23174%3B&amp;index=2&amp;md5=034189ca797bac851289527c6cae8111\" rel=\"nofollow\" shape=\"rect\">NANOBODY\u00ae<\/a> molecules to co-optimise proteins for therapeutically valuable properties. Following the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Flabgeniustx.com%2Flabgenius-research-collaboration-with-sanofi-yields-positive-results%2F&amp;esheet=54364500&amp;newsitemid=20251204759388&amp;lan=en-US&amp;anchor=success+of+their+first+collaboration&amp;index=3&amp;md5=51f29f481bc63340924f59f267e032d8\" rel=\"nofollow\" shape=\"rect\">success of their first collaboration<\/a>, LabGenius will apply the <b><i>EVA\u2122<\/i><\/b> platform to optimise NANOBODY\u00ae molecules for multiple new targets in the area of inflammation.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251204759388\/en\/2657331\/5\/LabGenius_Horizontal_Logo_Dark_2.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251204759388\/en\/2657331\/22\/LabGenius_Horizontal_Logo_Dark_2.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251204759388\/en\/2657331\/5\/LabGenius_Horizontal_Logo_Dark_2.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251204759388\/en\/2657331\/21\/LabGenius_Horizontal_Logo_Dark_2.jpg\"><\/a><\/p>\n<p>\n<i><b>\u201cWe are truly excited about this new collaboration with Sanofi,\u201d<\/b> <\/i>said LabGenius\u2019 CSO, Dr. Angus Sinclair. <i><b>\u201cThis partnership serves as strong validation of our platform\u2019s unique ability to tackle complex antibody co-optimisation challenges across a wide range of therapeutic targets, ultimately driving better outcomes for patients.\u201d<\/b><\/i>\n<\/p>\n<p>\n<b>About LabGenius Therapeutics<\/b>\n<\/p>\n<p>\nLabGenius Therapeutics is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company\u2019s discovery platform, <i><b>EVA\u2122<\/b><\/i>, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. LabGenius Therapeutics operates a hybrid business model that includes partnering with biotech and pharmaceutical companies in parallel with pursuing a wholly-owned therapeutic pipeline. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.labgeniustx.com&amp;esheet=54364500&amp;newsitemid=20251204759388&amp;lan=en-US&amp;anchor=www.labgeniustx.com&amp;index=4&amp;md5=66ce0252d353b8c98feb48ae8da20d01\" rel=\"nofollow\" shape=\"rect\">www.labgeniustx.com<\/a>, or connect on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flabgenius&amp;esheet=54364500&amp;newsitemid=20251204759388&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=ff52a837dec67a108be49bcf87c72d0b\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMedia: <a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#x6f;&#x3a;&#x70;&#x72;&#x65;ss&#64;&#108;&#97;&#x62;&#x67;&#x65;&#x6e;&#x69;&#46;u&#115;\" rel=\"nofollow\" shape=\"rect\">&#x70;r&#x65;&#115;s&#x40;&#108;&#x61;&#x62;g&#x65;&#110;i&#x2e;&#117;&#x73;<\/a><br \/>Corporate \/ business development: <a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x70;&#x61;&#114;t&#x6e;&#x65;&#114;s&#x68;&#x69;&#112;s&#x40;&#108;&#97;b&#x67;&#101;n&#x69;&#x2e;&#117;s\" rel=\"nofollow\" shape=\"rect\">&#x70;&#x61;&#114;t&#x6e;&#x65;&#114;sh&#x69;&#x70;&#115;&#64;&#x6c;&#x61;&#98;&#103;e&#x6e;&#x69;&#46;u&#x73;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (EVA\u2122) to optimise potential therapeutic NANOBODY\u00ae proteins for multiple new targets LONDON&#8211;(BUSINESS WIRE)&#8211;#AI&#8212;LabGenius Therapeutics (\u201cLabGenius\u201d), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62298","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\/ML-driven Antibody Optimisation Programmes - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\/ML-driven Antibody Optimisation Programmes - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (EVA\u2122) to optimise potential therapeutic NANOBODY\u00ae proteins for multiple new targets LONDON&#8211;(BUSINESS WIRE)&#8211;#AI&#8212;LabGenius Therapeutics (\u201cLabGenius\u201d), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T09:05:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251204759388\/en\/2657331\/22\/LabGenius_Horizontal_Logo_Dark_2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\\\/ML-driven Antibody Optimisation Programmes\",\"datePublished\":\"2025-12-04T09:05:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/\"},\"wordCount\":258,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251204759388\\\/en\\\/2657331\\\/22\\\/LabGenius_Horizontal_Logo_Dark_2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/\",\"name\":\"LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\\\/ML-driven Antibody Optimisation Programmes - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251204759388\\\/en\\\/2657331\\\/22\\\/LabGenius_Horizontal_Logo_Dark_2.jpg\",\"datePublished\":\"2025-12-04T09:05:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251204759388\\\/en\\\/2657331\\\/22\\\/LabGenius_Horizontal_Logo_Dark_2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251204759388\\\/en\\\/2657331\\\/22\\\/LabGenius_Horizontal_Logo_Dark_2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\\\/ML-driven Antibody Optimisation Programmes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\/ML-driven Antibody Optimisation Programmes - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/","og_locale":"en_US","og_type":"article","og_title":"LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\/ML-driven Antibody Optimisation Programmes - Pharma Trend","og_description":"The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (EVA\u2122) to optimise potential therapeutic NANOBODY\u00ae proteins for multiple new targets LONDON&#8211;(BUSINESS WIRE)&#8211;#AI&#8212;LabGenius Therapeutics (\u201cLabGenius\u201d), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/","og_site_name":"Pharma Trend","article_published_time":"2025-12-04T09:05:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251204759388\/en\/2657331\/22\/LabGenius_Horizontal_Logo_Dark_2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\/ML-driven Antibody Optimisation Programmes","datePublished":"2025-12-04T09:05:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/"},"wordCount":258,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251204759388\/en\/2657331\/22\/LabGenius_Horizontal_Logo_Dark_2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/","url":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/","name":"LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\/ML-driven Antibody Optimisation Programmes - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251204759388\/en\/2657331\/22\/LabGenius_Horizontal_Logo_Dark_2.jpg","datePublished":"2025-12-04T09:05:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251204759388\/en\/2657331\/22\/LabGenius_Horizontal_Logo_Dark_2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251204759388\/en\/2657331\/22\/LabGenius_Horizontal_Logo_Dark_2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/labgenius-therapeutics-announces-new-collaboration-with-sanofi-for-multiple-ai-ml-driven-antibody-optimisation-programmes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI\/ML-driven Antibody Optimisation Programmes"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62298"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62298\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}